Last reviewed · How we verify
ZM001 Injection
At a glance
| Generic name | ZM001 Injection |
|---|---|
| Sponsor | Beijing Immunochina Medical Science & Technology Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZM001 Injection CI brief — competitive landscape report
- ZM001 Injection updates RSS · CI watch RSS
- Beijing Immunochina Medical Science & Technology Co., Ltd. portfolio CI